BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2009

View Archived Issues

Omeprazole immediate-release exhibits favorable pharmacokinetics in GERD patients with gastroparesis

Read More

Safety, pharmacokinetic results with ZYH-1 in healthy subjects reported

Read More

GPR119 agonist MBX-2982 shows potential in treating diabetes

Read More

Promising first-in-human results for CAM-3001 in rheumatoid arthritis

Read More

Update on phase III results for eplivanserin in insomnia

Read More

Clinical studies of ENB-0040 in hypophosphatasia patients reported

Read More

11beta-HSD1 inhibition may benefit cognition

Read More

Novel ORL-1 antagonist with a favorable preclinical profile enters clinical trials as an analgesic

Read More

ActoGeniX receives FDA approval to initiate phase Ib clinical trials of AG-013 in cancer

Read More

FDA accepts for standard review IntelGenx's NDA for antidepressant CPI-300

Read More

Javelin completes safety study of Dyloject in the U.S. in acute postoperative pain

Read More

PharmaSwiss submits NDA in Israel for BioSante's Elestrin

Read More

Nippon Boehringer Ingelheim and Astellas launch Micombi for hypertension in Japan

Read More

GSK and Chroma to develop macrophage-targeted drugs using Chroma's ESM technology

Read More

Takeda completes tender offer for all outstanding shares of IDM Pharma common stock

Read More

Cytopia files IND with FDA for JAK2 inhibitor CYT-387

Read More

National Jewish Health reports results from preclinical animal testing of Ceragenix's CSA-13

Read More

Biovista presents efficacy results in a preclinical trial of BVA-601

Read More

Compugen reports therapeutic effects of novel peptide in animal model of IBS

Read More

Kyowa Hakko Kirin initiates phase II study for KW-0761 in T-cell lymphoma

Read More

Resolvyx initiates phase I RX-10001 trial for asthma and inflammatory diseases

Read More

Restanza shows 100% survival in confirmatory nonhuman primate anthrax study

Read More

Silence Therapeutics doses first patient in ATU-027 trial for solid tumors

Read More

Novel HIV-1 Nef protein ligands claimed by INSERM and CNRS for the treatment of AIDS

Read More

deCODE describes PDE4 inhibitors in development for the treatment of stroke

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing